Protein-protein  ||| S:0 E:16 ||| JJ
interactions  ||| S:16 E:29 ||| NNS
among  ||| S:29 E:35 ||| IN
signaling  ||| S:35 E:45 ||| VBG
pathways  ||| S:45 E:54 ||| NNS
may  ||| S:54 E:58 ||| MD
become  ||| S:58 E:65 ||| VB
new  ||| S:65 E:69 ||| JJ
therapeutic  ||| S:69 E:81 ||| JJ
targets  ||| S:81 E:89 ||| NNS
in  ||| S:89 E:92 ||| IN
liver  ||| S:92 E:98 ||| JJ
cancer  ||| S:98 E:105 ||| NN
( ||| S:105 E:106 ||| -LRB-
Review ||| S:106 E:112 ||| NNP
)  ||| S:112 E:114 ||| -RRB-
Numerous  ||| S:114 E:123 ||| JJ
signaling  ||| S:123 E:133 ||| JJ
pathways  ||| S:133 E:142 ||| NNS
have  ||| S:142 E:147 ||| VBP
been  ||| S:147 E:152 ||| VBN
shown  ||| S:152 E:158 ||| VBN
to  ||| S:158 E:161 ||| TO
be  ||| S:161 E:164 ||| VB
dysregulated  ||| S:164 E:177 ||| VBN
in  ||| S:177 E:180 ||| IN
liver  ||| S:180 E:186 ||| JJ
cancer ||| S:186 E:192 ||| NN
.  ||| S:192 E:194 ||| .
In  ||| S:194 E:197 ||| IN
addition ||| S:197 E:205 ||| NN
,  ||| S:205 E:207 ||| ,
some  ||| S:207 E:212 ||| DT
protein-protein  ||| S:212 E:228 ||| JJ
interactions  ||| S:228 E:241 ||| NNS
are  ||| S:241 E:245 ||| VBP
prerequisite  ||| S:245 E:258 ||| VBN
for  ||| S:258 E:262 ||| IN
the  ||| S:262 E:266 ||| DT
uncontrolled  ||| S:266 E:279 ||| JJ
activation  ||| S:279 E:290 ||| NN
or  ||| S:290 E:293 ||| CC
inhibition  ||| S:293 E:304 ||| NN
of  ||| S:304 E:307 ||| IN
these  ||| S:307 E:313 ||| DT
signaling  ||| S:313 E:323 ||| JJ
pathways ||| S:323 E:331 ||| NN
.  ||| S:331 E:333 ||| .
For  ||| S:333 E:337 ||| IN
instance ||| S:337 E:345 ||| NN
,  ||| S:345 E:347 ||| ,
in  ||| S:347 E:350 ||| IN
the  ||| S:350 E:354 ||| DT
PI3K ||| S:354 E:358 ||| FW
/ ||| S:358 E:359 ||| FW
AKT  ||| S:359 E:363 ||| FW
signaling  ||| S:363 E:373 ||| FW
pathway ||| S:373 E:380 ||| FW
,  ||| S:380 E:382 ||| ,
protein  ||| S:382 E:390 ||| NN
AKT  ||| S:390 E:394 ||| NNP
binds  ||| S:394 E:400 ||| NN
with  ||| S:400 E:405 ||| IN
a  ||| S:405 E:407 ||| DT
number  ||| S:407 E:414 ||| NN
of  ||| S:414 E:417 ||| IN
proteins  ||| S:417 E:426 ||| NNS
such  ||| S:426 E:431 ||| JJ
as  ||| S:431 E:434 ||| IN
mTOR ||| S:434 E:438 ||| NNP
,  ||| S:438 E:440 ||| ,
FOXO1  ||| S:440 E:446 ||| NNP
and  ||| S:446 E:450 ||| CC
MDM2  ||| S:450 E:455 ||| CD
to  ||| S:455 E:458 ||| TO
play  ||| S:458 E:463 ||| VB
an  ||| S:463 E:466 ||| DT
oncogenic  ||| S:466 E:476 ||| JJ
role  ||| S:476 E:481 ||| NN
in  ||| S:481 E:484 ||| IN
liver  ||| S:484 E:490 ||| JJ
cancer ||| S:490 E:496 ||| NN
.  ||| S:496 E:498 ||| .
The  ||| S:498 E:502 ||| DT
aim  ||| S:502 E:506 ||| NN
of  ||| S:506 E:509 ||| IN
the  ||| S:509 E:513 ||| DT
present  ||| S:513 E:521 ||| JJ
review  ||| S:521 E:528 ||| NN
was  ||| S:528 E:532 ||| VBD
to  ||| S:532 E:535 ||| TO
focus  ||| S:535 E:541 ||| VB
on  ||| S:541 E:544 ||| IN
a  ||| S:544 E:546 ||| DT
series  ||| S:546 E:553 ||| NN
of  ||| S:553 E:556 ||| IN
important  ||| S:556 E:566 ||| JJ
protein-protein  ||| S:566 E:582 ||| JJ
interactions  ||| S:582 E:595 ||| NNS
that  ||| S:595 E:600 ||| WDT
can  ||| S:600 E:604 ||| MD
serve  ||| S:604 E:610 ||| VB
as  ||| S:610 E:613 ||| IN
potential  ||| S:613 E:623 ||| JJ
therapeutic  ||| S:623 E:635 ||| JJ
targets  ||| S:635 E:643 ||| NNS
in  ||| S:643 E:646 ||| IN
liver  ||| S:646 E:652 ||| JJ
cancer  ||| S:652 E:659 ||| NN
among  ||| S:659 E:665 ||| IN
certain  ||| S:665 E:673 ||| JJ
important  ||| S:673 E:683 ||| JJ
pro-carcinogenic  ||| S:683 E:700 ||| JJ
signaling  ||| S:700 E:710 ||| JJ
pathways ||| S:710 E:718 ||| NN
.  ||| S:718 E:720 ||| .
The  ||| S:720 E:724 ||| DT
strategies  ||| S:724 E:735 ||| NNS
of  ||| S:735 E:738 ||| IN
how  ||| S:738 E:742 ||| WRB
to  ||| S:742 E:745 ||| TO
investigate  ||| S:745 E:757 ||| VB
and  ||| S:757 E:761 ||| CC
analyze  ||| S:761 E:769 ||| VB
the  ||| S:769 E:773 ||| DT
protein-protein  ||| S:773 E:789 ||| JJ
interactions  ||| S:789 E:802 ||| NNS
are  ||| S:802 E:806 ||| VBP
also  ||| S:806 E:811 ||| RB
included  ||| S:811 E:820 ||| VBN
in  ||| S:820 E:823 ||| IN
this  ||| S:823 E:828 ||| DT
review ||| S:828 E:834 ||| NN
.  ||| S:834 E:836 ||| .
A  ||| S:836 E:838 ||| DT
survey  ||| S:838 E:845 ||| NN
of  ||| S:845 E:848 ||| IN
these  ||| S:848 E:854 ||| DT
protein  ||| S:854 E:862 ||| NN
interactions  ||| S:862 E:875 ||| NNS
may  ||| S:875 E:879 ||| MD
provide  ||| S:879 E:887 ||| VB
alternative  ||| S:887 E:899 ||| JJ
therapeutic  ||| S:899 E:911 ||| JJ
targets  ||| S:911 E:919 ||| NNS
in  ||| S:919 E:922 ||| IN
liver  ||| S:922 E:928 ||| JJ
cancer ||| S:928 E:934 ||| NN
.  ||| S:934 E:936 ||| .
